Scarica l'app Stockscreener
288.45
2.01%
-5.93
Dopo l'orario di chiusura:
290.87
2.42
+0.84%
Precedente Chiudi:
$294.38
Aprire:
$291.96
Volume 24 ore:
665.31K
Relative Volume:
0.65
Capitalizzazione di mercato:
$7.27B
Reddito:
$1.77M
Utile/perdita netta:
$-123.74M
Rapporto P/E:
-31.46
EPS:
-9.17
Flusso di cassa netto:
$-95.21M
1 W Prestazione:
+0.72%
1M Prestazione:
+11.75%
6M Prestazione:
+474.60%
1 anno Prestazione:
+291.49%
Intervallo 1D:
$285.99
$305.21
Intervallo di 1 settimana:
$268.78
$305.21
Portata 52W:
$26.70
$317.72
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Confronta PRAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
288.45 | 7.42B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Reiterato | Oppenheimer | Outperform |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Will Praxis Precision Medicines Inc. stock see PE expansionVolume Spike & Low Volatility Stock Suggestions - ulpravda.ru
Praxis Precision (PRAX) Announces Key Leadership Changes - GuruFocus
Praxis Precision Medicines appoints new board members, promotes executives By Investing.com - Investing.com India
Praxis Precision Medicines Announces Key Management Appointments - TradingView — Track All Markets
Praxis Precision Medicines Announces New Board Appointments and Executive Promotions to Drive Growth and Commercial Readiness - Quiver Quantitative
New leadership steps in as Praxis prepares for potential brain drug launches - Stock Titan
Will Praxis Precision Medicines Inc. stock reach all time highs in 2025 - ulpravda.ru
How strong is Praxis Precision Medicines Inc. stock balance sheet2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - ulpravda.ru
Will Praxis Precision Medicines Inc. stock benefit from commodity pricesJuly 2025 Volume & Real-Time Market Sentiment Alerts - ulpravda.ru
Is Praxis Precision Medicines Inc. stock a smart buy before Fed meeting2025 Technical Patterns & Expert Approved Trade Ideas - ulpravda.ru
Is Praxis Precision Medicines Inc. stock a buy in volatile marketsJuly 2025 EndofMonth & Capital Efficient Trade Techniques - ulpravda.ru
Praxis rises on ulixacaltamide gaining Breakthrough Therapy status - MSN
PRAX Stock Surge: Time to Buy? - StocksToTrade
Praxis Precision Medicines Inc. (PRAX) secures analyst confidence after key FDA and trial wins - MSN
Praxis Precision Medicines Announces Major Underwritten Equity Offering - TipRanks
Praxis Precision Medicines Announces Underwritten Offering - TradingView — Track All Markets
Praxis Precision Medicines (PRAX) Valuation Check After A Strong 90 Day Share Price Run - Yahoo Finance
Praxis Precision stock rises as $575 million share sale clears at $260 - TechStock²
Praxis Precision Medicines edges down after $575 mln stock sale - TradingView — Track All Markets
Bright Minds Biosciences, Praxis Precision Medicines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Praxis Precision Medicines, Inc. Announces Proposed Public Offering - Sahm
Praxis Precision Prices $575 Mln Public Offering At $260/shr - Nasdaq
Praxis Precision (PRAX) Announces Public Offering of Stock and W - GuruFocus
Praxis Precision Medicines (PRAX) Announces $575M Public Offerin - GuruFocus
Praxis Precision prices $575M stock offering at $260 - MSN
Praxis Precision Medicines prices public offering at $260 per share By Investing.com - Investing.com Australia
Praxis Precision Medicines prices public offering at $260 per share - Investing.com
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - Yahoo Finance
Praxis Precision Medicines Announces Pricing of Public Offering of Common Stock at $260 Per Share - Quiver Quantitative
Biotech targeting CNS disorders lines up $575M stock sale - Stock Titan
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - GlobeNewswire Inc.
Praxis Precision Medicines announces proposed public offering By Investing.com - Investing.com Nigeria
Praxis Precision Medicines reports preliminary $925 million in cash and securities - Investing.com Nigeria
Praxis Precision Medicines reports preliminary $925 million in cash and securities By Investing.com - Investing.com South Africa
After-hours movers: Strategy, Mobileye, Ventyx Bioscience, Praxis - Investing.com
Praxis Precision Medicines slips after announcing equity offering plans - TradingView — Track All Markets
Praxis Precision Medicines stock falls on proposed public offering By Investing.com - Investing.com India
TD Cowen lifts Praxis Precision Medicines Inc. (PRAX) price target amid NDA for essential tremor treatment - MSN
Praxis Precision Medicines (PRAX) Valuation Check After Big Three Year Return And Price To Book Premium - Sahm
Deutsche Bank sets $111 target for Praxis Precision shares - MSN
Praxis Precision Medicines Earnings Notes - Trefis
Praxis Precision Medicines stock rises as FDA grants breakthrough designation By Investing.com - Investing.com South Africa
Praxis Precision Medicines stock rises as FDA grants breakthrough designation - Investing.com Australia
Praxis Precision Medicines (PRAX) Gets a Buy from Chardan Capital - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines stock gains as TD Cowen reiterates Buy on FDA breakthrough status - Investing.com Canada
Praxis Precision Medicines stock gains as TD Cowen reiterates Buy on FDA breakthrough status By Investing.com - Investing.com South Africa
Praxis: Priced For Perfection Heading Into 2026 (NASDAQ:PRAX) - Seeking Alpha
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug - ts2.tech
Praxis Precision Medicines stock gets FDA boost as H.C. Wainwright maintains Buy - Investing.com Canada
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Praxis Precision Medicines Inc Azioni (PRAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):